SAB Therapeutics announced its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases.

Merck is globally committed to an antimicrobial stewardship encompassing surveillance, R&D, and health policy.